Who
Miranda Jayne Toledano
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Entera Bio; Director, Journey Medical; Director, NexGel; Director, Compass Therapeutics.
In numbers
- Trades disclosed
- 39
- Buys
- 6
- Sells
- 0
- Bought
- $123K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 25 Jun 2021
- Last trade
- 7 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 14 Jul 2026filed 16 Jul 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —347,567 at $0.00 | filing |
| 14 Jul 2026filed 16 Jul 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —72,993 at $0.00 | filing |
| 14 Jul 2026filed 16 Jul 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —347,567 at $0.00 | filing |
| 14 Jul 2026filed 16 Jul 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —72,993 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | DERM Journey MedicalPharmaceuticals | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | DERM Journey MedicalPharmaceuticals | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | DERM Journey MedicalPharmaceuticals | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | DERM Journey MedicalPharmaceuticals | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 29 Dec 2025filed 30 Dec 2025 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $20K11,000 at $1.81 | filing |
| 5 Aug 2025filed 7 Aug 2025 | DERM Journey MedicalPharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —136,842 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —43,860 at $0.00 | filing |
| 25 Jun 2025filed 7 Jul 2025 | DERM Journey MedicalPharmaceuticals | SEC FORM 4 Code A | —7,173 at $0.00 | filing |
| 31 Jul 2024filed 2 Aug 2024 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 31 Jul 2024filed 2 Aug 2024 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —124,121 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.